Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $38.00 at Wells Fargo & Company

Kymera Therapeutics (NASDAQ:KYMR - Free Report) had its target price upped by Wells Fargo & Company from $30.00 to $38.00 in a research note released on Monday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

A number of other equities analysts also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 17th. Oppenheimer restated an outperform rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Finally, B. Riley lifted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a neutral rating in a research report on Tuesday, July 9th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $43.80.

Kymera Therapeutics Stock Up 2.6 %

Shares of NASDAQ KYMR traded up $1.06 during trading hours on Monday, hitting $42.50. The company had a trading volume of 392,267 shares, compared to its average volume of 666,950. The stock has a market capitalization of $2.61 billion, a P/E ratio of -16.92 and a beta of 2.22. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $48.70. The firm's 50 day moving average is $37.09 and its 200-day moving average is $37.14.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to analysts' expectations of $12.55 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The company's revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.67) earnings per share. On average, sell-side analysts predict that Kymera Therapeutics will post -2.86 earnings per share for the current year.

Insider Activity

In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Joanna Horobin sold 8,500 shares of the stock in a transaction on Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jared Gollob sold 23,145 shares of the business's stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the transaction, the insider now directly owns 95,470 shares of the company's stock, valued at approximately $4,373,480.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 502,345 shares of company stock valued at $19,279,932. 15.82% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 5.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company's stock valued at $135,848,000 after purchasing an additional 278,287 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company's stock worth $101,778,000 after buying an additional 72,351 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth $792,000. BVF Inc. IL boosted its stake in Kymera Therapeutics by 8.9% in the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company's stock valued at $131,419,000 after buying an additional 422,797 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in Kymera Therapeutics in the first quarter valued at about $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.